Nadav Kidron - 18 Mar 2026 Form 3 Insider Report for Alpha Tau Medical Ltd. (DRTS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 19:04:07 UTC
Prior SEC filing
18 Mar 2026
Next SEC filing
27 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nadav Kidron

Key filing fact

Nadav Kidron filed Form 3 for Alpha Tau Medical Ltd. (DRTS) on 18 Mar 2026.

Key facts

  • This page summarizes Nadav Kidron's Form 3 filing for Alpha Tau Medical Ltd. (DRTS).
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 19:04.

Change

  • Previous filing in this sequence was filed on 18 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001351779 Primary reporting owner

KIDRON NADAV

Relationship
Director
Address
20 MAMILLA, JERUSALEM, ISRAEL
Signature
/s/ Nadav Kidron
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DRTS holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,986
Date
18 Mar 2026
Ownership
Direct
DRTS holding

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,767
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1
DRTS holding

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,680
Date
18 Mar 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
35,554
Exercise price
$2.79
Footnotes
F3
DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
15,527
Exercise price
$6.41
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These ordinary shares represent the unvested portion of a grant of restricted share units, which vests in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.

Footnote F2

These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

Footnote F3

These are options to acquire ordinary shares, which options will vest in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.

Footnote F4

These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .